<DOC>
	<DOC>NCT00615459</DOC>
	<brief_summary>The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.</brief_summary>
	<brief_title>A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any studyrelated procedure Cooperative out patients with a diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the Global initiative for chronic obstructive lung disease (GOLD) Guidelines, 2006) and: 1. Smoking history of at least 10 pack years (current or previous smokers) 2. Postbronchodilator forced expiratory volume in 1 second (FEV1) &lt; 80% and ≥30% of the predicted normal value. 3. Postbronchodilator FEV1/Forced vital capacity (FVC) &lt; 70% Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the runin period Patients requiring longterm oxygen therapy for chronic hypoxemia Patients who have had a respiratory tract infection within 6 weeks prior to Visit Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Any patient with active cancer or a history of cancer with less than 5 years disease free survival time Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at Visit 1 or randomization is prolonged Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the runin period. Patients unable to successfully use a dry powder inhaler device, MDI or perform spirometry measurements Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Chronic obstructive pulmonary disease, indacaterol, tiotropium, placebo controlled</keyword>
</DOC>